Shots:

• The P-II ELARA study involves assessing the efficacy & safety of Kymriah in adult patients with r/r FL in 30 sites across 12 countries
• Results: @median follow-up of 11 mos.- CRR (66%)- ORR (86%) with one-time therapy infusion- median DOR in all responders- PFS & OS were not reached- response rates were consistent across high-risk patient subgroups- estimated DOR in patients with CR and PFS rates @6mos. (94% & 76%)- no patient experienced grade 3/4 cytokine release syndrome. The regulatory submissions based on a P-II study is expected in late 2021
• Kymriah is 1st FDA-approved CAR-T cell therapy for r/r ALL in pediatric & adult patients and r/r adult DLBCL

  Ref: Globe Newswire | Image: Novartis